| 鼻咽癌的免疫治疗进展* |
| |
| 引用本文： | 邱艳芳,刘志刚,赵宇,王晖.鼻咽癌的免疫治疗进展*[J].中国肿瘤临床,2016,43(23):1053-1057. |
| |
| 作者姓名： | 邱艳芳 刘志刚 赵宇 王晖 |
| |
| 作者单位： | 作者单位:湖南省肿瘤医院,中南大学湘雅医学院附属肿瘤医院放疗科,肿瘤放射治疗转化医学湖南省重点实验室(长沙市410013) |
| |
| 基金项目： | 本文课题受国家自然科学基金项目(编号81472802)，湖湘青年英才项目(编号2016RS3036) |
| |
| 摘 要： | 鼻咽癌是一种与EB病毒（Epstein-Barrvirus，EBV ）相关的恶性肿瘤，单纯放疗或同步放化疗是鼻咽癌重要的治疗手段，且取得较好的疗效，但局部晚期或远处转移的鼻咽癌患者预后仍较差。目前，免疫治疗已成为实体肿瘤治疗的新方向，其主要通过激活机体的免疫系统从而达到抗肿瘤的目的。本文旨在探讨免疫治疗如过继性免疫治疗、肿瘤疫苗、免疫节点抑制剂等在鼻咽癌治疗中的进展。
|
| 关 键 词： | 鼻咽癌 EB病毒 免疫治疗? 过继性免疫治疗? 肿瘤疫苗? 免疫节点抑制剂 |
| 收稿时间： | 2016-07-19 |
Research progress on immunotherapy of nasopharyngeal carcinoma |
| |
| Institution: | Department of Radiation Oncology, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Key Laboratory of Translational Radiation Oncology, Hunan Province, Central South University, Changsha 410013, China |
| |
| Abstract: | Nasopharyngeal cancer (NPC) is an Epstein–Barr virus-associated malignant tumor. Radiation alone or concurrent chemo-radiotherapy is the principal treatment method and can generally achieve excellent efficacy for NPC patients. However, the prognosis of locoregionally advanced disease or distant metastasis remains poor. Currently, immunotherapy has become a new treatment of sol-id tumors, and it is mainly activating the antitumor immune system of the body. The review aims to explore the progress of immuno-therapy, including adoptive immunotherapy, tumor vaccines, and immune checkpoint inhibitors in NPC treatment. |
| |
| Keywords: | nasopharyngeal carcinoma Epstein-Barr virus immunotherapy adoptive immunotherapy tumor vaccine checkpoint inhibi-tor |
| 本文献已被 万方数据 等数据库收录！ |
| 点击此处可从《中国肿瘤临床》浏览原始摘要信息 |
| 点击此处可从《中国肿瘤临床》下载免费的PDF全文 |
